KemPharm, which is developing abuse-deterrent versions of widely-prescribed pain medications, announced terms for its IPO on Friday.
The Coralville, IA-based company plans to raise $52 million by offering 4 million shares at a price range of $12 to $14. At the midpoint of the proposed range, KemPharm would command a fully diluted market value of $207 million.
KemPharm, which was founded in 2006, plans to list on the NASDAQ under the symbol KMPH. Cowen & Company and RBC Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of April 13, 2015.
